Publications

Dr. Neuwelt has written or edited several books and book chapters, and has over 200 peer reviewed scientific publications.

Selected Clinical Research Publications:

The History of BBB Disruption

Neuwelt EA, Hill SA, Frenkel EP. Osmotic blood-brain barrier modification and combination chemotherapy: Concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. Neurosurgery 15:362-366, 1984.

Neuwelt EA, Hill SA, Frenkel EP, Diehl JT, Maravilla KR, Vu LH, Clark WK, Rapoport SI, Barnett PA, Lewis SE, Ehle AL, Beyer CW, Jr. Osmotic blood-brain barrier disruption: Pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors. Cancer Treat Rep 65(suppl):39-43, 1981.

Neuwelt EA, Maravilla KR, Frenkel EP, Rapoport SI, Hill SA, Barnett PA. Osmotic blood-brain barrier disruption: Computerized tomographic monitoring of chemotherapeutic agent delivery. J Clin Invest 64:684-688, 1979.

Clinical Studies: BBBD Chemotherapy Efficacy

Guillaume DJ, Doolittle ND, Gahramanov S, Hedrick NA, Delashaw JB, Neuwelt EA. Intra-Arterial Chemotherapy with Osmotic Blood-Brain Barrier Disruption for Aggressive Oligodendroglial tumors: Results of a Phase I Study. Neurosurgery, 66:48-58,discussion 58, 2010..

Angelov L, Doolittle ND, Kraemer DF, Siegal T, Barnett GH, Peereboom DM, Stevens G, McGregor J, Jahnke K, Lacy CA, Hedrick NA, Shalom E, Ference S, Bell S, Sorenson L, Tyson RM, Haluska M, Neuwelt EA. Blood-brain disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience with 149 patients. J Clin Oncol 27:3503-3509, 2009.

Doolittle ND, Abrey LE, Shenkier TN, Siegal T, Bromberg JEC, Neuwelt EA, Soussain C, Jahnke K, Johnson P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 111:1085-1093, 2008.

Jahnke K, Kraemer DF, Knight KR, Fortin D, Bell S, Doolittle ND, Muldoon LL, Neuwelt EA. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. Cancer 112(3):581-8, 2008.

Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D, Neuwelt EA. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol 77(3):279-84, 2006.

Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA. Association of total dose intensity of chemotherapy in primary CNS lymphoma (human non-AIDS) and survival. Neurosurg 48:1033-1041, 2001.

Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, Braziel R, Dana B. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. Classic Papers and Current Comments: Highlights of Neurologic Cancer Research – J Clin Oncol 5:360-370, 2000.

Doolittle ND, Miner ME, Hall WA, Siegal T, Hanson EJ, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL, Neuwelt EA. Safety and efficacy of a multi-center study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of malignant brain tumors. Cancer 88:637-647, 2000.

Dahlborg SA, Petrillo A, Crossen JR, Roman-Goldstein S, Doolittle ND, Fuller KH, Neuwelt EA. The potential for complete and durable response in non-glial primary brain tumors in pediatric patients and young adults with enhanced chemotherapy delivery. Cancer J Sci Am 4:110-124, 1998.

Williams PC, Henner WD, Roman-Goldstein S, Dahlborg SA, Brummett RE, Tableman M, Dana BW, Neuwelt EA. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurg 37:17-28, 1995.

Neuwelt EA, Hill SA. Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. J Neuro-Oncol 4:195-207, 1987.

Clinical Studies: BBBD and Cognitive Function

Neuwelt EA, Guastadisegni PE, Varallyay P, Doolittle ND. Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol 26:258-65, 2005.

McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA. Cognitive outcomes and long-term follow-up after enhanced chemotherapy delivery for primary central nervous system lymphomas. Neurosurg 46:51-61, 2000.

Clinical Studies: Antibody Delivery to the Brain

Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW Jr, Lacy CA, Tyson RM, Haluska M, Hedrick NA, Varallyay C, Neuwelt EA. Potential of immunochemotherapy and radioimmunotherapy in relapsed primary CNS lymphoma. Leukemia Lymphoma 48:1712-20, 2007.

Tyson RM, Kraemer DF, Hunt MA, Orbay P, Muldoon LL, Steeg PS, Neuwelt EA. Chemothrapy with or without trastuzumab, a monoclonal antibody, and blood-brain barrier disruption for breast cancer brain metastases. Expert Review Anti-Cancer Therapy 3:97-112, 2006.

Neuwelt EA, Barnett PA, Hellström KE, Hellström I, Beaumier P, McCormick CI, Wigel R. Delivery of melanoma-specific immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res 48:4725-4729, 1988.

Neuwelt EA, Specht D, Larson S, Krohn K, Hellström K, Hellström I, Dahlborg SA, Barnett P. Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurgery 20:885-895, 1987.

Neuwelt EA, Specht HD, Hill SA. Permeability of human brain tumor to 99mTc-glucoheptonate and 99mTc-Albumin: Implications for monoclonal antibody therapy. J Neurosurg 65:194-198, 1986.

Clinical Studies: Nanoparticle Delivery and Imaging

Gahramanov S, Muldoon LL, Kraemer DF, Li X, Hamilton BE, Rooney WD, Neuwelt EA. Radiographic diagnosis of pseudoprogression in patients with GBM after chemoradiation using DSC-MRI with ferumoxytol vs. gadoteridol and correlation with survival. Radiology. Accepted 2012.

Hasan DM, Amans M, Tihan T, Hess C, Guo Y, Cha S, Su H, Martin AJ, Lawton MT, Neuwelt EA, Saloner DA, Young WL. Feruxmoytol-enhanced MRI to image inflammation within human brain arteriovenous malformations: a pilot investigation. Transl Stroke Res. (Suppl 1):S166-S173, 2012.

Thompson EM, Guillaume DJ, Dósa E, Li X, Nazemi KJ, Gahramanov S, Hamilton BE, Neuwelt EA. Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. J Neurooncol, 109(1):105-114, 2012.

Hamilton BE, Nesbit GM, Dosa E, Gahramanov S, Rooney B, Nesbit EG, Raines J, Neuwelt EA. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2- weighted MRI in neuroimaging. American Journal of Roentgenology, 197(4):981-8, 2011.

Dosa E, Tuladhar S, Muldoon LL, Hamilton, BE, Rooney WD, Neuwelt, EA. Magnetic resonance imaging using ferumoxytol improves the visualization of central nervous system vascular malformations. Stroke, 42(6):1581-8, 2011.

Dosa E, Guillaume DJ, Haluska M, Lacy CA, Hamilton BE, Njus JM, Rooney WD, Kraemer DF, Muldoon LL, Neuwelt EA. Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. Neuro Oncology, 13:251-60, 2011.

Gahramanov S., Raslan A., Muldoon LL, Hamilton BE, Rooney WD, Varallyay CG, Njus JM, Haluska M, Neuwelt, EA. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol versus gadoteridol: a pilot study. International J Radiation Oncology Biology Physics, 79:514-23, 2011.

Thompson EM, Dosa E, Kraemer DF, Neuwelt EA. Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. J Neuro-Oncology, 103(2):353-60, 2011.

Thompson EM, Dosa E, Kraemer DF and Neuwelt EA (2010) Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery 67:87-93.

Weinstein J, Varallyay C, Dosa E, Gharmanov S, Hamilton B, Rooney W, Muldoon LL, Neuwelt EA. Superparamagnetic Iron Oxide Nanoparticles: Diagnostic Magnetic Resonance Imaging and Therapeutics in CNS Pathology, a Review. In Press, J Cerebral Blood Flow & Metabolism, 2009.

Neuwelt EA, Hamilton BE, Varallyay CG, Rooney WR, Edelman RD, Jacobs PM, Watnick SG. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?. Kidney International. 75(5):465-74, 2009.

Neuwelt EA, Várallyay CG, Manninger S, Solymosi D, Haluska M, Hunt MA, Nesbit G, Stevens A, Jerosch-Herold M, Jacobs PM, Hoffman JM. Potential of ferumoxytol nanoparticle MR imaging, perfusion, and angiography in CNS maliganacy: A Pilot Study. Neurosurgery. 60:601-11, 2007.

Murillo T, Neuwelt E. USPIOs to enhance the diagnostic potential of ultrasound in tumor and other inflammatory lesions (editorial). AJNR Am J Neuroradiol 26:1305-6, 2005.

Hunt MA, Bago AG, Neuwelt EA. Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10. AJNR Am J Neuroradiol 26:1084-1088, 2005.

Manninger SP, Muldoon LL, Nesbit G, Murillo T, Jacobs PM, Neuwelt EA. An exploratory study of ferumoxtran-10 nanoparticles as a blood brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. AJNR: Am J Neuroradiol 26:2290-2300, 2005.

Neuwelt EA, Várallyay P, Bagó AG, Muldoon LL, Nesbit G, Nixon R. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumors. Neuropath Applied Neurobiol 30:456-471, 2004.

Varallyay P. Nesbit G. Muldoon LL. Nixon RR. Delashaw J. Cohen JI. Petrillo A. Rink D. Neuwelt EA. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am J Neuroradiol 23:510-519, 2002.

Clinical Studies: Chemoprotection

Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, Rassekh SR, Chang KW, Fligor BJ, Rajput K, Sullivan M, Neuwelt EA. Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale. J Clin Oncol. 30(19):2408-17, 2012.

Neuwelt EA and Brock P (2010) Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 28:1630-1632.

Stenstrom DA, Armijo-Medina H, Watnick S, Doolittle ND, Kaufman JA, Peterson DR, Bubalo J, Neuwelt EA. Can N-acetylcysteine prevent Contrast Induced Nephropathy: Premature Phase III Trials. J Vascular & Interventional Radiology. 19:309-18, 2008.

Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clinical Oncol 25:1190-5, 2007.

Neuwelt EA., Gilmer-Knight K, Lacy C, Nicholson HS, Kraemer DF, Doolittle ND, Hornig G, Muldoon LL. Toxicity Profile of Delayed High Dose Sodium Thiosulfate in Children Treated with Carboplatin in conjunction with Blood-Brain-Barrier Disruption. Pediatr Blood Cancer. 47:174-82, 2006.

Doolittle ND, Muldoon LL, Brummett RE, Tyson RM, Lacy C, Bubalo JS, Kraemer DF, Heinrich MC, Henry JA, Neuwelt EA. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 7:493-500, 2001.

Neuwelt EA, Brummett RE, Doolittle ND, Muldoon LL, Kroll RA, Pagel MA, Dojan R, Church V, Remsen LG, Bubalo JS. First evidence of otoprotection against carboplatin-induced hearing loss with a two compartment model in patients with CNS malignancy. J Pharmacol Exp Therapeut 286:77-84, 1998.

Clinical Studies: Miscellaneous

Guillaume DJ, Knight K, Marquez C, Kraemer DF, Bardo DM, Neuwelt EA. Cerebrospinal fluid shunting and hearing loss in patients treated for medulloblastoma. J Neurosurg Pediatr. 9(4):421-7, 2012.

Abla O, Weitzman S, Blay J-Y, O'Neill B, Abrey L, Neuwelt EA, Doolittle ND, Baehring J, Pradhan K, Martin SE, Guerrera M, Shah S, Ghequeuieres H, Silver M, Betensky R, Batchelor T. Primary CNS Lymphoma in Children and Adolescents: A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clinical Cancer Research, 17(2):346-52, 2011.

Dillard TH, Gultekin SH, Delashaw JB Jr, Yedinak CG, Neuwelt EA, Fleseriu M. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary, 14(1):80-91, 2011.

Recent Reviews

Neuwelt EA, Bauer B, Fahlke C, Fricker G, Iadecola C, Janigro D, Leybaert L, Molnar Z, O'Donnell M, Povlishock J, Saunders N, Sharp F, Stanimirovic D, Watts R, Drewes L. Engaging Neuroscience to Advance Brain Barriers Translational Research. Nature Reviews Neuroscience, 12(3):169-82, 2011.

Thompson EM, Frenkel EP, Neuwelt EA. The Paradoxical Effect of Bevacizumab in the Therapy of Malignant Gliomas. Neurology, 76(1):87-93, 2011.Neuwelt EA, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B, Grammas P, Nedergaard M, Nutt J, Pardridge W, Rosenberg GA, Smith Q, Drewes LR. Strategies for Advancing Brain-Barriers Translational Research. Lancet Neurology, 7:84-96. 2008.

Muldoon LL, Soussain C, Jahnke K, Johanson C, Tiegal T, Smith QR, Hall W, Hynynen K, Senter P, Peereboom DM, Neuwelt EA. Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check. J Clinical Oncol 25(16):2295-305, 2007.

Doolittle ND, Peereboom DM, Christoforidis GA, Hall WA, Brock P, Campbell K, Dickey DT, Muldoon LL, O’Neill BP, Palmieri D, Peterson DR, Pollock B, Soussain C, Smith Q, Tyson RM, Neuwelt EA. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the eleventh annual blood-brain barrier consortium meeting. J Neurooncol. 81(1):81-91, 2007.

Jahnke K, Doolittle ND, Muldoon LL, Neuwelt EA. Implications of the blood-brain barrier in primary central nervous system lymphoma. Neurosurg Focus. 21(5):E11, 2006.

Muldoon LL, Tratnyek P, Jacobs PM, Doolittle ND, Christoforidis GA, Frank J, Lindau M, Lockman PR, Manninger S, Qiang Y, Spence AM, Stupp SI, Zhang M, Neuwelt EA. Imaging and nanomedicine for diagnosis and therapy in the CNS: Report of the eleventh annual blood-brain barrier disruption consortium meeting. AJNR Am J Neuroradiol 27:715-21, 2006.

Doolittle ND, Abrey LE, Bleyer WA, Brem S, Davis TP, Dore-Duffy P, Drewes LR, Hall WA, Hoffman JM, Korfel A, Martuza R, Muldoon LL, Peereboom D, Peterson DR, Rabkin SD, Smith Q, Stevens GHJ, Neuwelt EA. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual blood-brain barrier disruption consortium meeting. Clin Cancer Res 11:421-428, 2005.

Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurg 54:131-142, 2004.

Kraemer DF, Fortin D, Neuwelt EA. Chemotherapeutic Dose intensification for treatment of malignant brain tumors: Recent developments and future directions. Current Neurol Neurosci Reports 2:216-224, 2002.

Crossen JR, Garwood A, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation induced encephalopathy. J Clin Oncol 12:627-642, 1994.

Selected Preclinical Research Publications:

Preclinical Studies: Therapy Studies in Animal Models

Wu YJ, Muldoon LL, Gahramanov S, Kraemer DF, Marshall DJ, Neuwelt EA. Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. J Neurooncol. 2012 in press.

Muldoon LL, Lewin SJ, Dosa E, Kraemer DK, Pagel MA, Doolittle ND, Neuwelt EA. Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma. Clin Cancer Res, 17(8):2207-15, 2011.

Neuwelt A, Wu J, Knap N, Losin M, Neuwelt EA, Pagel M, Warmann S, Fuchs J, Czauderna P, Wozniak M. Utilizing acetaminophen's toxicity mechanism in the cisplatin treatment of hepatocarcinoma and hepatoblastoma cell lines. Neoplasia, 11(10): 1003-1011, 2009.

Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Brown RD, Kraemer DF, Soussain C, Neuwelt EA. Efficacy and MRI of rituximab and methotrexate treatment in a nude rat central nervous system lymphoma model. Neuro-Oncology 11(5):503-13, 2009.

Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Kraemer DF, Neuwelt EA. Bevacizumab and Carboplatin Increase Survival and Asymptomatic Tumor Volume in a Glioma Model. Neuro-Oncology 11(2):142-50, 2009.

Soussain C, Muldoon LL, Varallyay C, Jahnke K, DePaula L, Neuwelt EA. Characterization and Magnetic Resonance Imaging of a Rat Model of Human B-Cell Central Nervous System Lymphoma. Clinical Cancer Research 13: 2504-2511 2007.

Staverosky JA, Leslie L. Muldoon, Guo S, Evans AJ, Neuwelt EA, Clinton GM. Herstatin, an autoinhibitor of the EGF receptor family, blocks the intracranial growth of glioblastoma. Clin Cancer Res 11:335-340, 2005.

Neuwelt EA, Thrun LA, Walker-Rosenfeld S, Cave AT, Muldoon LL. Effect of antigenic heterogeneity on the efficacy of targeted chemotherapy in brain tumor xenografts. Neurosurg 53:1406-1413, 2003.

Remsen LG, Marquez C, Garcia R, Thrun L, Neuwelt EA. Efficacy and toxicity after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung xenograft model. Int J Rad Oncol Biol Physics 51:1045-1049, 2001.

Remsen LG, Trail PA, Hellström I, Hellström KE, Neuwelt EA. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurg 46:704-709, 2000.

Preclinical Studies: Nanoparticle Delivery and Imaging

Gahramanov S, Muldoon LL, Li X, Neuwelt EA. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol. Radiology, 261(3):796-804, 2011.

Muldoon LL, Gahramanov S, Li X, Marshall DJ, Kraemer DF and Neuwelt EA (2010) Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. Neuro Oncol 13(1): 51-60, 2011.

Li X, Rooney WD, Varallyay CG, Gahramanov S, Muldoon LL, Goodman JA, Tagge IJ, Selzer AH, Pike MM, Neuwelt EA and Springer CS, Jr. Dynamic-contrast-enhanced-MRI with extravasating contrast reagent: rat cerebral glioma blood volume determination. J Magn Reson 206:190-199, 2010.

Varallyay CG, Muldoon LL, Gahramanov S, Wu YJ, Goodman JA, Li X, Pike MM, Neuwelt EA. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 29:853-60, 2009.

Wu YJ, Muldoon LL, Varallyay C, Markwardt S, Jones RE, Neuwelt EA. In Vivo Leukocyte Labeling and Characterization with Intravenous Ferumoxides/Protamine Sulfate for Cellular Magnetic Resonance Imaging. Am J Physiol – Cell Physiol 293:C1698-708, 2007.

Muldoon LL, Manninger S, Pinkston KE, Neuwelt EA. Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery 57:785-96, 2005.

Muldoon LL, Varallyay P, Kraemer DF, Kiwic G, Pinkston K, Walker-Rosenfeld SL, Neuwelt EA. Trafficking of superparamagnetic iron oxide particles (Combidex) from brain to lymph nodes in the rat. Neuropathology Applied Neurobiology 30:70-79, 2004.

Muldoon LL, Pagel MA, Kroll RA, Roman-Goldstein S, Jones RS, Neuwelt EA. A physiologic barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery. AJNR Am J Neuroradiol 20:217-222, 1999.

Neuwelt, EA, Weissleder R, Nilaver G, Kroll RA, Roman-Goldstein S, Szumowski J, Pagel MA, Jones RS, Remsen LG, McCormick CI, Shannon EM, Muldoon LL. Delivery of virus-sized iron oxide particles to rodent CNS neurons. Neurosurgery, 34:777-784, 1994.

Preclinical Studies: Chemoprotection

Dickey DT, Muldoon LL, Doolittle ND, Peterson DR, Kraemer DF, Neuwelt EA. Effect of N-acetylcysteine dose and route of administration on chemoprotection against cisplatin-induced nephrotoxicity in rat models. Cancer Chemotherapy Pharmacology 62:235-241, 2008.

Harned TM, Kalous O, Neuwelt A, Loera J, Neuwelt EA, Iovine P, Reynolds CP. Sodium thiosulfate (STS) administered six hours after cisplatin does not compromise anti-neuroblastoma activity. Clinical Cancer Res 14(2):533-40, 2008.

Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Therapeut 314:1052-8, 2005.

Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Therapeut 312:424-431, 2005.

Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR, Muldoon LL. Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Therapeut 309:594-599, 2004.

Dickey DT, Muldoon LL, Kraemer DF, and Neuwelt EA. Protection against cisplatin-induced ototoxicity and nephrotoxicity by N-acetylcysteine in a rat model. Hearing Res 193:25-30, 2004.

Neuwelt EA, Pagel MA, Hasler BP, Deloughery TG, Muldoon LL. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 61:7868-7874, 2001.

Muldoon LL, Pagel MA, Kroll RA, Brummett RE, Doolittle ND, Zuhowski EG, Egorin MJ, Neuwelt EA. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res, 6:309-315, 2000.

Neuwelt, EA, Brummett RE, Remsen LG, Kroll RA, Pagel MA, McCormick CA, Goitjens S, Muldoon LL. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res 56:706-709, 1996.

Preclinical Studies: BBBD Delivery to the CNS

Neuwelt EA, Barnett P, McCormick CI, Remsen LG, Kroll RA, Sexton, G. Differential permeability of a human brain tumor xenograft in the nude rat: The impact of tumor size and method of administration on optimizing delivery of biologically diverse agents. Clin Cancer Res, 4:1549-1556, 1998.

Remsen LG, McCormick CI, Sexton G, Pearse HD, Garcia R, Neuwelt EA. Decreased delivery and acute toxicity of chemotherapy given with osmotic blood-brain barrier disruption and cranial irradiation in a rodent model: The issue of sequence. Clin Cancer Res 1:731-739, 1995.

Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO Davidson BL, Neuwelt EA. Delivery of herpes virus and adenovirus to nude rat intracerebral tumors following osmotic blood-brain barrier disruption. Proc Natl Acad Sci USA 92:9829-9833, 1995.

Neuwelt EA, Barnett PA, Ramsey FL, Hellström I, Hellström KE, McCormick CI. Dexamethasone decreases the delivery of tumor-specific monoclonal antibody to both intracerebral and subcutaneous tumor xenografts. Neurosurg 33:478-484, 1993.

Neuwelt EA, Pagel MP, Dix R: Delivery of UV-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier. J Neurosurg 74:475-479, 1991.

Neuwelt EA, Barnett P, McCormick CI, Frenkel EP, Minna JD. Osmotic blood-brain barrier modification: Monoclonal antibody, albumin, and methotrexate delivery to CSF and brain. Neurosurg 17:419-423, 1985.

Preclinical Studies: Miscellaneous

Pommier SJ. Quan GG. Christante D. Muller P. Newell AE. Olson SB. Diggs B. Muldoon L. Neuwelt E. Pommier RF. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells. Annals of Surgical Oncology. 17(2):613-23, 2010.

Thompson EM, Whitney NL, Wu YJ, Neuwelt EA. Inhibiting αV integrins Decreases the Malignant Characteristics of Medulloblastoma J Neurosurg Pediatr. Accepted 2012.

Wu YJ, Muldoon LL, Dickey DT, Lewin SJ, Varallyay CG, Neuwelt EA. Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. Neoplasia.11:187-195, 2009.

Tritz R, Hickey MJ, Lin AH, Hadwiger P, Sah DW, Neuwelt EA, Mueller BM, Kruse CA. FAPP2 gene downregulation increases tumor cell sensitivity to Fas-induced apoptosis. Biochem Biophys Res Commun 383(2):167-71, 2009.

Tritz R, Mueller BM, Hickey MJ, Lin AH, Gomez GG, Hadwiger P, Sah DWY, Muldoon L, Neuwelt EA, Kruse CA. siRNA down-regulation of the PATZ1 gene in human glioma cells increases their sensitivity to apoptotic stimuli. Cancer Therapy 6:865-876, 2008.

Smith JR. Henderson WW. Rosenbaum JT. Neuwelt EA. Moses AV. Cultured human endothelial cells expressing HIV-1 Vpu and Tat support the expansion of malignant B cells from primary central nervous system lymphoma. British J Ophthalmology. 92(2):297-9, 2008.